The U.S. FDA granted breakthrough device designation to Mursla Bio Ltd.'s Evoliver. The biopsy blood test uses extracellular vesicles to survey hepatocellular carcinoma in high-risk cirrhotic patients ...

EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation from the FDA.

Here we have listed five blood tests that can help early detection ... as they are at increased risk for developing hepatocellular carcinoma. A study published in Hepatology revealed that routine ...

Mursla Bio has revealed outcomes from the MEV01 clinical study of its ‘EvoLiver’ blood test for the surveillance of hepatocellular carcinoma (HCC), primary liver cancer in high-risk cirrhotic ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

The American Cancer Society recommends people at average risk of colorectal cancer start screening at age 45, now several ...

Laboratory test results are shown in Table ... Given the continued lesion growth, hepatocellular carcinoma was suspected. The blood alpha-fetoprotein level was 11 ng per milliliter.

Mursla Bio, a Cambridge UK and Boston US leader in Extracellular Vesicle (EV) science, has received FDA approval for its lead ...